Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00425555
First received: January 22, 2007
Last updated: November 16, 2016
Last verified: November 2016